Bioactive glass S53P4 for bone infection in the forefoot of people with diabetes
Compares bioactive glass S53P4 with usual care for diabetic forefoot bone infection.
Key facts
- Who runs it
- ASST Ovest Milanese
- Where
- Italy7 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- RCT on Bioactive Glass S53P4 in Diabetic Foot Osteomyelitis in the Forefoot (DFORCT)
- Status
- Recruiting
- People taking part
- 140 people, planned
- Started
- 21 Mar 2024
- Expected to end
- 30 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Bioactive Glass
- Standard of Care
- Record updated
- 29 April 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with diabetes who have a bone infection (osteomyelitis) in the front part of the foot that needs surgery. It compares bioactive glass S53P4 with standard surgical care.
- Age
- 18 Years to 100 Years
- Sex
- Male and female
- Disease stage
- Bone infection in the forefoot, confirmed by imaging and culture. It has not improved after at least 2 up to 6 weeks of antibiotics and/or comes with soft tissue infection, abscess, phlegmon or dead tissue. Surgery to clean the infection is planned. Type I diabetes for at least 5 years, or type II diabetes.
- Earlier treatment
- At least 2 up to 6 weeks of antibiotics taken by mouth or vein without response (or soft tissue infection). No surgery or catheter procedure to restore blood flow in the affected foot in the month before joining.
- Biomarker or test result
- Good blood flow in the affected leg: pulses felt at the ankle, and/or ABPI >0.7 and <1.2, and/or TcPO2 on the top of the foot ≥36 mmHg. HbA1c not above 109 mmol/mol (> 12%).
Main reasons for not taking part
- Kidney failure on dialysis
- Charcot foot in the affected foot, or major amputation of the other leg
- Taking corticosteroids, bisphosphonates, immunosuppressants or other drugs that affect bone or healing
- Bedridden or unable to walk
- Life expectancy under one year, or too ill for surgery under local or regional anesthesia
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Written informed consent obtained
- Male or female patients >= of 18 years old
- They should have type I since at least 5 years or type II DM
- They should have a diagnosis - confirmed by imaging and culture - of OM localized in the forefoot not responding for at least 2 up to 6 weeks to systemic antibiotic therapy and/or associated with soft tissue infection, abscess, phlegmon, necrosis, and for which a surgical debridement is indicated
- They should have palpable pulses on TP or DP at the ankle in the affected limb, and/or ABPI >0.7 and <1.2 and /or TcPO2 at dorsum of the foot ≥36 mmHg
- They should be able to accomplish with the procedures and prescriptions indicated by the Study protocol, particularly with the offloading prescription, as well as they should be willing and able to attend and respect the program of control visits and medications
- Anatomical area: forefoot
Who cannot take part
- They should not have undergone surgical or endovascular revascularization in the affected foot in the month preceding the enrollment
- They should not be taking corticosteroids, bisphosphonates, immunosuppressants, and more in general any drug which might interfere with bone metabolism or tissue repair, in thejudgment of investigators
- They should not be too ill to sustain a surgical procedure under loco-regional anesthesia
- Participation in another interventional studies within 45 days prior to the start of the present study
- They should not have severe disease which might interfere with the expected course of the disease and therapy
- Hypersensitivity to any product ingredient(s) or history of anaphylactic reactions
- They should not have metabolic decompensation as witnessed by HbA1c >109 mmol/mol (> 12%)
- They should not have major amputation on the contra-lateral limb
- They should not have acute or chronic Charcot's foot in the affected foot
- They should not have ESRD in dialysis
- They should not be bedridden or not ambulating
- They should not have a life expectancy shorter than one year
- Predictable poor compliance or inability to communicate well with the investigator
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
This trial is currently available in Italy.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The Study will be a prospective multicenter randomized trial, focused on the management of acute and chronic Osteomilytis in Diabetic Foot patients. The aim of this Study will be to compare the effectiveness and safety of S53P4 bioactive glass, medical device class III used as per its CE mark indication and Instruction For Use, in the surgical management of OM in the forefoot performed as per local surgical standard of care, in the same indications in a group of Diabetic Foot patients admitted in highly specialized dedicated centers.
Read full original descriptionShow less
Participants will randomized into two groups:
* Patients in Group A will be treated with surgical removal of the affected bone, debridement of infected soft tissues and systemic antibiotic therapy targeted on the sampling on the bone during the surgical procedure, with or without use of bone substitutes (with the only exception of Bioactive glasses) according to the judgement of the operator as per normal practice. * Patients in Group B will be debrided as well and the infected bone will be debrided without eliminating completely the structure of the bone, but instead preserving the cortex, while all the soft bone visibly infected will be removed and then replaced with Bioactive glass, as per IFU, (S53P4 - Bonalive® granules and putty, Bonalive Biomaterials Ltd. Finland) and then closed for primary intention whenever possible.
The 2 groups in the trial
- Standard of Care - Osteomyelitis treatmentExisting treatment, for comparison
Subjects randomized in this group will be treated according to standard of care for the surgical managment of Osteomyelitis in the forefoot in patient suffering from diabetic foot syndrome. All standard of care approaches will be allowed (e.g use of bone sobsitutes, cements, cements loaded with antibiotics etc) with the only exception of Bioactive Glasses.
Treatment: Standard of Care
- Bioactive GlassTreatment being tested
Subjects randomized in this group will be treated using the S53P4 Bioactive Glass of Bonalive Biomaterials Ltd; in the form of: * Bonalive Granules 2.5 CC (0.5-0.8 MM) * Bonalive Putty 2.5 CC (SIRINGA 0.5-0.8 MM) The quantity that will be implanted will vary according to the bone cavity of each patient.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A National, Prospective, Randomized, Multicenter, Controlled Comparison of Bioactive Glass S53P4 Versus Standard of Care Treatment of Diabetic Foot Osteomyelitis in the Forefoot
- Plain-language title
- Bioactive glass S53P4 for bone infection in the forefoot of people with diabetesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06388603, who can take part
- Record updated
- 29 April 2024